Inventor · disambiguated record
Saad Kenderian
Also filed as: KENDERIAN SAAD · KENDERIAN SAAD J
8 granted patents·19 pending applications·119 citations·filing 2015–2025
83Inventor score
Top patents by PatentIndex Score
27 records- 0197US9815901B2Treatment of cancer using a CD123 chimeric antigen receptorBROGDON JENNIFER·Filed 2015·Granted Nov 14, 2017·94 cites·40 claims
- 0295US10357514B2Treatment of cancer using anti-CD19 Chimeric Antigen ReceptorUNIV PENNSYLVANIA·Filed 2015·Granted Jul 23, 2019·18 cites·45 claims
- 0385US10568947B2Treatment of cancer using a CLL-1 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Feb 25, 2020·6 cites·38 claims
- 0483US10703819B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Jul 7, 2020·1 cites·33 claims
- 0579US2023220090A1Treatment of cancer using a cd123 chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 0673US2025171547A1Epha3 directed car-t cells for treatment of tumorsMAYO FOUND MEDICAL EDUCATION & RES·Filed 2024·Application pending·0 cites
- 0771US12264189B2Methods and materials for treating cancerMAYO FOUND MEDICAL EDUCATION & RES·Filed 2019·Granted Apr 1, 2025·0 cites·10 claims
- 0870US11591404B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 0965US2025387431A1Treating cancer with chimeric antigen receptors that bind to trailshort polypeptidesMAYO FOUND MEDICAL EDUCATION & RES·Filed 2023·Application pending·0 cites
- 1065US2020215171A1Treatment of cancer using a cll-1 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1163US2025250317A1Methods and materials for treating graft-versus-host diseaseMAYO FOUND MEDICAL EDUCATION & RES·Filed 2025·Application pending·0 cites
- 1263US2025325586A1Treating cancerMAYO FOUND MEDICAL EDUCATION & RES·Filed 2023·Application pending·0 cites
- 1362US12139544B2EphA3 directed CAR-T cells for treatment of tumorsHUMANIGEN INC·Filed 2020·Granted Nov 12, 2024·0 cites·21 claims
- 1462US2019388471A1Treatment of cancer using anti-cd19 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1560US2024158869A1Factors for optimizing immunotherapyKITE PHARMA INC·Filed 2023·Application pending·0 cites
- 1660US2021145881A1Methods and materials for treating graft-versus-host diseaseMAYO FOUND MEDICAL EDUCATION & RES·Filed 2019·Application pending·0 cites
- 1758US2021284714A1Materials and methods for treating cancerHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1854US2022040229A1Materials and methods for treating cancerHUMANIGEN INC·Filed 2019·Application pending·0 cites
- 1954US2024158467A1Materials and methods for treating cancerHUMANIGEN INC·Filed 2022·Application pending·0 cites
- 2051US12257286B2Methods and materials for treating cancerMAYO FOUND MEDICAL EDUCATION & RES·Filed 2019·Granted Mar 25, 2025·0 cites·8 claims
- 2151US2024384266A1Treating cancerMAYO FOUND MEDICAL EDUCATION & RES·Filed 2022·Application pending·0 cites
- 2250US2022401488A1Methods and materials for using engineered mesenchymal stem cells to treat inflammatory conditions and degenerative diseasesKENDERIAN SAAD J·Filed 2020·Application pending·0 cites
- 2349US2021145830A1Materials and methods for treating cancerMAYO FOUND MEDICAL EDUCATION & RES·Filed 2019·Application pending·0 cites
- 2448US2025269022A1Assessing and treating cancerMAYO FOUND MEDICAL EDUCATION & RES·Filed 2022·Application pending·0 cites
- 2544US2025313608A1Materials and methods for treating cancerMAYO FOUND MEDICAL EDUCATION & RES·Filed 2025·Application pending·0 cites
- 2642US2021214723A1Materials and methods for treating cancerMAYO FOUND MEDICAL EDUCATION & RES·Filed 2019·Application pending·0 cites
- 2740US2019336504A1Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitorGILL SAAR·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Saad Kenderian files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →